> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Stakeholder Notification for GDUFA Reauthorization Participation
- URL: https://www.fdaweb.com/stakeholder-notification-for-gdufa-reauthorization-participation/
- Published: 2020-09-14T12:00:00.000Z
- Updated: 2026-09-14T16:28:36.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5147639

*Federal Register* notice: FDA is requesting that stakeholders notify it about their intent to participate in periodic consultation meetings on reauthorizing the Generic Drug User Fee Amendments of 2017 (GDUFA). At the end 9/2022, new legislation will be required for FDA to continue collecting user fees for subsequent fiscal years for the generic drug program. Under the program, FDA is required to consult with a range of stakeholders in developing recommendations for the next GDUFA program. To view the notice, click [here](https://s3.amazonaws.com/public-inspection.federalregister.gov/2020-20334.pdf?ref=fdaweb.com).